Talk:MeNZB

From WikiProjectMed
Jump to navigation Jump to search

Ěthis was an effective immunisation :]

yeah it really was.
har har.


219.89.103.84 02:51, 2 September 2007 (UTC)HAHHA[reply]

External links modified (January 2018)

Hello fellow Wikipedians,

I have just modified 2 external links on MeNZB. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

This message was posted before February 2018. After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than regular verification using the archive tool instructions below. Editors have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the RfC before doing mass systematic removals. This message is updated dynamically through the template {{source check}} (last update: 18 January 2022).

  • If you have discovered URLs which were erroneously considered dead by the bot, you can report them with this tool.
  • If you found an error with any archives or the URLs themselves, you can fix them with this tool.

Cheers.—InternetArchiveBot (Report bug) 18:39, 23 January 2018 (UTC)[reply]

Bexsero (= 4CMenB = MenB-4C) protects from Gonorrhea

https://en.wikipedia.org/wiki/Gonorrhea

https://en.wikipedia.org/wiki/MeNZB

--

https://pubmed.ncbi.nlm.nih.gov/29048985/

2018 May 4

The recent discovery that meningococcal group B OMVs may protect against the related Neisseria species N.gonorrhoeae. There are 2 OMV-containing group B vaccines available, the new recombinant protein-based Bexsero® developed by Novartis and VA-MENGOC-BC® developed by the Finlay institute in Cuba.

Also, a third group B vaccine based on two recombinant factor H binding proteins (Trumenba®, Pfizer), has recently been licenced but it does not include OMV.

--

https://www.immunize.org/askexperts/experts_meningococcal_b.asp#recommendations

  • Available data indicate that protective antibody levels wane in most recipients within 1–2 years of completion of the primary series.
  • Bexsero (MenB-4C, GSK) is a 2-dose series with doses given at least 1 month apart.
  • Evidence to date suggests no impact of MenB vaccine on meningococcal B carriage (may protect an individual from invasive disease but is unlikely to impact transmission of the bacteria to others)
  • Approved ages 10–25 years in USA.

In Finland approved for all ages including >50 years:

https://laakeinfo.fi/Medicine.aspx?m=17572&i=GLAXOSMITHKLINE_BEXSERO

---

https://www.nature.com/articles/s41541-021-00388-3

Title: Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect

29 October 2021

Real-world evidence showed risk reductions of 69% for meningococcal serogroup W clonal complex 11 disease and 40% for gonorrhea after 4CMenB immunization.

--

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00812-4/fulltext

Title: Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study

April 12, 2022

Complete MenB-4C vaccination series was 40% (95% CI 23–53) effective against gonorrhoea and partial MenB-4C vaccination series was 26% (12–37) effective.

Complete vaccination = two MenB-4C doses administered 30–180 days apart.

--

https://reference.medscape.com/drug/trumenba-bexsero-meningococcal-group-B-vaccine-999974

Bexsero. 0.5 mL IM as a 2-dose series administered at least 1 month apart

ACIP recommendations for at risk adults

Booster dose: Administer 1 year after primary series completed and repeat booster dose every 2-3 yr if risk remains

At risk individuals include e.g. Microbiologists routinely exposed to Neisseria meningitidis

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

--

https://gskpro.com/en-gb/products/bexsero/real-world-evidence/

Study design: 3-year observational study

Bexsero was introduced for all infants in the UK in September 2015.

Infants were administered the vaccine at 2, 4 and 12 months, which resulted in a 75% reduction in meningitis B incidence in all fully eligible children in England. incidence rate ratio, 0.25; 95% CI, 0.19 to 0.36).

--

https://www.medicines.org.uk/emc/product/5168

Intervals between Primary Doses: Not less than 1 month or 2 months, depending on age.

There are no data in adults above 50 years of age.

91.159.188.253 (talk) 22:29, 15 June 2022 (UTC)[reply]

Retrieved from "https://mdwiki.org/wiki/Talk:MeNZB"